RxDoctor Payments Data

Matthew Seigerman

Interventional Cardiology · Fairfield, CTNPI 1164817623

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,280 of the $5,446 with a category attached, or 60.2%. 9 manufacturers reported payments, led by Medtronic at 26.1% of the total. Reporting peaked in 2021 at $2,585 and has fallen 88.6% since, to $294 in 2024. That places this record below the midpoint for interventional cardiology clinicians in CT, where the typical reported total is $5,446.

$5,446in general payments, 2019–2025

Across 58 payments — averaging $93.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Edwards Lifesciences$1K
  • Abbott$790
  • Inari Medical, Inc.$674
  • Abiomed$382
  • Shockwave Medical, Inc$358
  • plus $510 from 3 others

What the payments were for

  • Travel & lodging$2,16640%
  • Food & beverage$3,28060%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,446 in reported general payments places this provider in the 50th percentile of 73 interventional cardiology providers in Connecticut.

See all interventional cardiology providers in Connecticut

Medicare billing

Part B allowed, 2024
$252,704
Medicare patients
1,700
Services billed
3,804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis20$545,932
EliquisApixaban311$339,381
FarxigaDapagliflozin Propanediol127$145,292
Repatha SureclickEvolocumab155$95,289
JardianceEmpagliflozin85$88,973
XareltoRivaroxaban76$81,219
EntrestoSacubitril/Valsartan82$65,015
Praluent PenAlirocumab48$25,377
BrilintaTicagrelor18$15,929
VascepaIcosapent Ethyl41$14,325
Metoprolol Succinate816$9,589
Ezetimibe310$7,015
Rosuvastatin Calcium569$6,949
Atorvastatin Calcium525$4,856
Losartan Potassium578$4,489

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Fairfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →